News

Researchers generate a stem cell-based model to study an ultra-rare disease that causes childhood parkinsonism

Researchers from the Bellvitge Biomedical Research Institute (IDIBELL), the Sant Joan de Déu Research Institute (IRSJD), Sant Pau Research Institute (IIB Sant Pau) and the UB generated the first model of this disease that reproduce patients’ characteristics and response to treatment.

Leer más about Researchers generate a stem cell-based model to study an ultra-rare disease that causes childhood parkinsonism

Kickoff to the XarSMART initiative, which aims to promote the transfer of medical technology in Catalonia

This is a proposal coordinated by IDIBELL and financed by AGAUR in which 13 other institutions participate. XarSMART will offer projects access to experts in regulatory, eHealth, data science and precision medicine.

Leer más about Kickoff to the XarSMART initiative, which aims to promote the transfer of medical technology in Catalonia

A bioinformatics program will accelerate the diagnosis of hereditary cancer

Bioinformaticians from the Bellvitge Biomedical Research Institute (IDIBELL) and geneticists from the Molecular Diagnostic Laboratory of the Catalan Institute of Oncology (ICO) joined forces to develop a program that facilitates genetic variants classification, as it collects and combines the available information to offer a first classification of the variants.

Leer más about A bioinformatics program will accelerate the diagnosis of hereditary cancer

Bellvitge Hospital and IDIBELL lead clinical trial to reduce the impact of infections in heart transplant patients

It is a project that delves into personalized medicine. This trial has been financed by the Carlos III Health Institute through R&D projects call in 2019, and by a grant from the Spanish Society of Cardiology.

Leer más about Bellvitge Hospital and IDIBELL lead clinical trial to reduce the impact of infections in heart transplant patients

Bellvitge Hospital and IDIBELL successfully test a new method to compare two multiple sclerosis treatments

The study compares the use of two drugs through what they have called a natural experiment, which opens the doors to a new research methodology to compare highly effective treatments, minimizing possible biases in the analysis of the different groups.

Leer más about Bellvitge Hospital and IDIBELL successfully test a new method to compare two multiple sclerosis treatments

VacunAcció once again challenges students to get vaccinated against misinformation

This course, the educational project has been implemented in a group of Baccalaureate from the Escola Pia of Igualada

Leer más about VacunAcció once again challenges students to get vaccinated against misinformation

Consumption of processed foods increases the risk of cancer

This is the largest and most complete study carried out on the subject, it has included more than 450,000 people from 9 European countries and has analyzed the relationship of diet with 25 different types of cancer. The work concludes that replacing 10% of the intake of processed products with others that are not reduces the risk of suffering any type of cancer.

Leer más about Consumption of processed foods increases the risk of cancer

IDIBELL’s technology, licensed to LoopDx, starts a crowdequity campaign

Between 2018 and 2019, the IDIBELL and Bellvitge University Hospital researcher Joan Sabater, in collaboration with the start-up LoopDx, developed SeptiLoop, a rapid sepsis diagnostic kit. The result of this project was patented and licensed to the company itself.

Leer más about IDIBELL’s technology, licensed to LoopDx, starts a crowdequity campaign
Scroll to Top